Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 7:30 PM
Ignite Modification Date: 2025-12-24 @ 7:30 PM
NCT ID: NCT04917003
Eligibility Criteria: Inclusion Criteria: 1. Subjects who were diagnosed as moyamoya disease by the diagnostic criteria recommended by the Research Committee on MMD of the Ministry of Health and Welfare of Japan in 2012. 2. Suzuki stage: 2-5 stage 3. Age: between 18 and 65 years old 4. Subjects present with ischemic stroke or transient ischemic attack. 5. Subjects who plan to accept the first EDAS surgery. 6. Informed consent obtained from patient or patient's surrogate Exclusion Criteria: 1. Acute ischemic stroke occurred within one month. 2. Suffered Intracranial hemorrhage before 3. Subjects with large infarction spread widely over the territory of a main arterial trunk 4. Aneurysms in the main arterial trunk 5. Severe cardiac diseases like atrial fibrillation,valvular disease,heart failure, infective endocarditis and so on. 6. Malignant tumors or severe disordered function of the heart, lung, liver or kidney. 7. Severe hemostatic disorder or severe coagulation dysfunction. 8. Uncontrolled diabetes mellitus with a serum fasting blood glucose level\>300 mg/dL, or requires insulin; hypertension with a systolic blood pressure over 180 mmHg or a diastolic blood pressure over 110 mmHg. 9. Severe injury on upper limbs. 10. Pregnant or lactating women. 11. Life expectancy is less than 3 years. 12. Patients who are not suitable for this trial considered by researchers for other reasons
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 65 Years
Study: NCT04917003
Study Brief:
Protocol Section: NCT04917003